Butyrate, a physiologically occurring agent, has been reported to decrease constitutively high expressed p53 levels in transformed cells. To elucidate whether butyrate also inhibits DNA-damage-induced p53 response we investigated the eects of butyrate and the anticancer drug mitomycin C in normal C3H10T1/2 cells harbouring wild-type p53. In comparison with p53-de®cient ®broblasts we examined p53 protein level, cell cycle arrest, dierentiation, and apoptosis. Butyrate induced G1 phase arrest, dierentiation, and p53-independent increase in p21 waf1/cip1 protein. Moreover, butyrate induced p53-independent apoptosis, which was, as well as p53-mediated apoptosis, associated with a dose-dependent increase in Bax and c-Myc protein. Pretreatment with butyrate repressed dose-dependently mitomycin-C-induced p53 accumulation and interfered with p53-dependent cell cycle arrest. Butyrate further partially inhibited p53-mediated apoptosis, but low doses of butyrate were more eective than higher concentrations. This was re¯ected in an enhanced decrease in c-Myc and Bax protein in response to mitomycin C with low concentrations of butyrate. Our data indicate that the dierentiation stimulus of butyrate, in association with p21 waf1/cip1 induction, and apoptosis, may explain antineoplastic eects of butyrate. Co-carcinogenic features of butyrate may result from inhibition of p53-mediated DNA damage response.
Introduction
Chemotherapy and radiation are widely used for cancer treatment. Common features of many anticancer drugs and radiation are induction of DNA damage followed by the activation of the tumor suppressor protein p53 as a mediator of their cellular eects (Goetz and Montenarh, 1995) . The short-lived p53 protein acts as a transcriptional regulator capable of both stimulating and repressing gene expression. In response to DNA damage nuclear accumulation of wild-type p53 is induced by transcription-independent stabilization of the protein (Kastan et al., 1991; Fritsche et al., 1993) . As the p53 C-terminus was shown to recognize and bind damaged DNA Jayaraman and Prives, 1995) and since binding to DNA protects the protein from rapid proteolysis (Molinari and Milner, 1995) , this stabilization may be the result of p53-DNA interaction. p53-DNA interaction promotes further sequence-speci®c DNA-binding by the central core domain of p53 and subsequently leads to transactivation of target genes (Jayaraman and Prives, 1995) .
The accumulation and activation of wild-type p53 in DNA-damaged cells results at least in two pathways, cell cycle arrest and apoptosis. Cell cycle progression is stopped by p53 in G1 (Kuerbitz et al., 1992) and possibly also in G2 phase of the cell cycle (Stewart et al., 1995; Agarwal et al., 1995; Siegel et al., 1995) . The p53-dependent G1 arrest is mediated by direct transactivation of the p21 waf1/cip1 gene which encodes a universal inhibitor of cyclin-dependent kinases (Harper et al., 1993; Xiong et al., 1993; El-Deiry et al., 1994) . Transcriptional activation has also been implicated in p53-dependent induction of apoptosis: experimental overexpression of p53 is associated with a decreased bcl-2 expression, an apoptosis-suppressing gene, and an increased gene expression of bax, encoding for a cellular antagonist of Bcl-2 (Haldar et al., 1994; Miyashita et al., 1994; Selvakumaran et al., 1994) . The ratio between Bax and Bcl-2 is believed to determine whether a cell will enter apoptosis or survive after receiving an apoptotic trigger (Oltvai et al., 1993) . The bax gene is a direct target gene of p53 (Miyashita and Reed, 1995) , and upregulation of Bax protein in response to g-radiation is also observed in vivo (Kitada et al., 1996) . However, for some cell types transcriptional activation does not seem to be necessary for p53-induced apoptosis (Caelles et al., 1994; Wagner et al., 1994) . For this reason other mechanisms through which p53 induces apoptosis such as repression of cell survival genes or interaction with components of the enzymatic machinery for apoptotic cleavage are discussed.
Induction of cell cycle arrest and apoptosis by p53 accumulation seem to be regulated separately (Lin and Benchimol, 1995; Abrahamson et al., 1995) , but both pathways protect against replication and ampli®cation of genetic damage. Cell cycle arrest is believed to provide time for DNA repair prior to the onset of DNA synthesis and mitosis, while severe DNA damage is considered to result in induction of apoptosis. In addition, p53 may contribute to tumor suppression through a third mechanism. Recent ®ndings suggest a direct role for p53 in DNA repair, besides its transcription factor activity. p53 does not only bind single-and double-stranded DNA (Steinmeyer and Deppert, 1988; Kern et al., 1991) , but also catalyzes DNA renaturation and p53 strand transfer in vitro (Oberosler et al., 1993; Bakalkin et al., 1994) . There is increasing evidence that p53 directly regulates or indirectly stimulates the DNA repair machinery in vivo , possibly by induction of gadd45 expression, another p53 target gene .
The loss of p53 function is linked to development of neoplasia. In human cancer alterations of the p53 gene are among the most frequent mutations (Hollstein et al., 1991) . Thus, p53 can be considered as molecular guardian of the genome ' (Lane, 1992) . This model is supported by the increased tumor incidence in p53-knockout mice (Donehower et al., 1992) , which correlates with an elevated frequency of spontaneous chromosomal aberrations in these animals (Bouer et al., 1995) . Embryonic ®broblasts de®cient in p53 were reported to be resistant to diverse chemotherapeutic drugs (Lowe et al., 1993) . Since missing or attenuated p53 response may promote carcinogenesis by survival of damaged cells and accumulation of further mutations, we were interested in studies on the physiologically occurring agent butyrate. In an earlier study it has been shown that butyrate reduces the p53 level in transformed 3T6 cells which constitutively express high amounts of p53 (Wintersberger and Mudrak, 1984) . In the present study we investigated whether butyrate also inhibits DNA-damage-induced p53 response.
Butyrate is a natural product found in food and is produced by bacterial fermentation of bran and starch within the human colon. It serves as the most important energy source for normal colorectal cells (Cummings, 1981) . Besides this, epidemiological studies suggest an important role of butyrate in the prevention of colorectal cancer by high dietary ®bre intake (Stemmermann and Yatani, 1972; Howe et al., 1992) . Well-examined in vitro eects are growth inhibition and promotion of dierentiation in normal as well as in transformed cells (Kruh, 1982) . Butyrate-treated cells strongly alter cell morphology and a number of transformed cells are reversed to a normal phenotype. The induced growth arrest in early G1 phase (Wintersberger et al., 1983 ) is associated with a rapid repression of c-myc expression, followed by a decrease in the level of p53 mRNA (Toscani et al., 1988; Heruth et al., 1993) . In addition, gene expression of c-fos (Toscani et al., 1988) , c-jun and junB is stimulated (Mollinedo et al., 1993) . Recently, butyrate became of interest for tumor therapy of melanoma (Soballe and Herlyn, 1994) and leukemia (Warell et al., 1993) as dierentiating agent.
Earlier studies on butyrate focused on the promotion of dierentiation in tumor cells and were mainly done in colorectal carcinoma and leukemic cell lines, which are often de®cient in wild-type p53 (Hague et al., 1993; Calabresse et al., 1993; Steinman et al., 1994) . Therefore, we chose the murine C3H10T1/2 as a nontumor cell line harbouring wild-type p53 for our experiments. For the ®rst time, the interaction of butyrate with the p53-dependent DNA-damage response was systematically investigated in the present study. We compared the eects of butyrate and its combination with the anticancer drug mitomycin C in C3H10T1/2 cells with the eects in p53-de®cient ®broblasts. The in¯uence of butyrate on p53 protein level, cell cycle arrest, dierentiation, and apoptosis was examined. To get further insight into the interacting molecular mechanisms, p21 waf1/cip1 , Bax, and c-Myc protein levels were investigated by¯ow cytometric analysis.
We report here that the induction of growth arrest and dierentiation by butyrate does not depend on p53 expression but correlates with a p53-independent increase in p21 waf1/cip1 protein. With longer incubation we observed p53-independent butyrate-induced apoptosis associated with a dose-dependent induction of Bax and c-Myc protein. Moreover, butyrate inhibits dose-dependently DNA-damage-induced p53 accumulation and further modulates p53-dependent cell cycle arrest as well as subsequent apoptosis. Low doses of butyrate were more eective than higher concentrations in inhibition of mitomycin-C-induced apoptosis and in inhibition of associated increase in c-Myc and Bax. We suggest that with low concentrations the dierentiation stimulus of butyrate, in association with p21 waf1/cip1 induction, may predominate and antagonize DNAdamage-induced apoptosis.
Results

Dose-and time-dependent inhibition of mitomycin-Cinduced p53 accumulation by butyrate in C3H10T1/2 cells
To investigate the interference of butyrate with the DNA-damage-induced p53 response, we studied the non-transformed murine ®broblast cell line C3H10T1/2 containing wild-type p53 (Coleman et al., 1994) . C3H10T1/2 cells were preincubated for dierent periods of time with butyrate in concentrations as indicated (0 to 20 mM). Cells were then treated with 10 mg/ml mitomycin C or mock-treated. Sixteen hours later p53 protein content was evaluated by indirect immuno¯uorescence assay with the p53-speci®c antibody PAb122 (Figure 1 ). An antibody directed against T-antigen (T-Ag) of SV40 was used as speci®city control. The classi®cation of p53¯uorescence intensities combined the percentage of positive nuclei with their brilliance on a scale from 0 to 4 as described in Materials and methods.
Cells treated with butyrate only showed no nuclear p53 (Figure 1, open symbols) . In response to Figure 1 Inhibition of p53 accumulation by pretreatment with butyrate. C3H10T1/2 cells were pretreated for various times with various concentrations of butyrate (0, 2, 5, 10, 20 mM) and then treated with 10 mg/ml mitomycin C for 16 h (®lled symbols). As control cells were treated with butyrate only (open symbols). For indirect immuno¯uorescence cells were ®xed and stained with the p53-speci®c antibody PAb122. PAb1605 was used as speci®ty control. Relative p53 levels were evaluated as described in Materials and methods. Values represent the mean of three independent experiments. Cells treated with butyrate only never showed p53-speci®c nuclear staining mitomycin C p53 accumulation was inhibited by butyrate in correlation with the concentration used ( Figure 1 , ®lled symbols). Furthermore, inhibition was enhanced by longer cellular pretreatment with butyrate. An immuno¯uorescence belonging to the experiments of Figure 1 is shown in Figure 2 . Data obtained with the p53-speci®c antibody PAb122 could be con®rmed by PAb421 and PAb240 (Table 1) . Mitomycin-C-induced p53 accumulation and inhibition by butyrate was also detected with PAb1620 in immuno¯uorescence analysis but with lower fluorescence intensities (Table 1) . For 10 mM butyrate inhibition of p53 accumulation by butyrate was con®rmed by immunoprecipitation with PAb122 (data not shown). In murine NIH3T3 and in African green monkey cells, TC7, pretreatment with 10 mM butyrate for 20 h also suppressed p53 accumulation (Table 2) .
For all following experiments butyrate was applicated to cells 18 h before mitomycin C treatment in order to guarantee a maximum inhibition of p53 accumulation.
The physiologically occurring compound 3D-bhydroxybutryate, a metabolite of butyrate in the bloodstream, did not inhibit p53 accumulation when applied to cells at concentrations used for butyratemediated inhibition (data not shown).
p53-independent induction of dierentiation by butyrate
Following cellular treatment with millimolar concentrations of butyrate for 1 day and longer, C3H10T1/2 ®broblasts showed changes in cellular morphology as determined by light microscopy ( Figure 3 , 2 days 10 mM butyrate). Cells¯attened, enlarged and formation of stress ®bres could be observed. The cell density decreased and a small percentage of the cells became bi-and multinucleated later on. After treatment with 10 mM butyrate for 2 days butyrate was removed and cells were passaged further for 5 days in normal medium. In many cells these changes in cellular morphology were not reversible after removal of butyrate, which is an indication for dierentiation ( Figure 3 ). During subsequent culture in normal medium about 13% of these dierentiated C3H10T1/ 2 cells showed fragmentation of the nucleus which was followed by cell death. Longer incubation with butyrate for 10 days before withdrawal increased the percentage of dierentiated cells.
Because butyrate-induced dierentiation has been reported to be accompanied by a decrease in p53 mRNA level (Dony et al., 1985; Toscani et al., 1988) , we compared the eects of butyrate in C3H10T1/2 cells with those in murine p53-de®cient ®broblasts ( Figure  3 ). Although untreated low passages of p53-negative cells already showed a low percentage of binucleated cells, the presence of butyrate in the medium markedly increased the number of binucleated cells. Low-passage p53-de®cient cells showed the same morphological changes during treatment which indicates that butyrate-induced dierentiation does not depend on p53 expression. In most cells the morphological alterations were not reversible after removal of butyrate since fragmentation of the nucleus occurred and was followed by cell death (Figure 3 ).
Butyrate interferes with mitomycin-C-induced cell cycle arrest by p53-independent induction of p21
Butyrate has been reported to induce a cell cycle arrest in early G1 phase (Wintersberger et al., 1983) . As shown by cytometric cell cycle analysis ( Figure 4A ), treatment with 2 to 5 mM butyrate for 34 h in C3H10T1/2 cells resulted in a decrease in S phase while cells accumulated in G1 phase. Cells treated with 10 mM butyrate showed no signi®cant accumulation in G1 phase. We further Figure 2 Immuno¯uorescence of the data shown in Figure 1 with the p53-speci®c antibody PAb122. (a) untreated cells; (b) 5 mM butyrate for 20 h, (c) 10 mg/ml mitomycin C for 16 h; (d) 5 mM butyrate simultaneously added with 10 mg/ml mitomycin C for 16 h; (e) 5 mM butyrate added 8 h before 10 mg/ml mitomycin C for 16 h; (f) 5 mM butyrate added 20 h before 10 mg/ml mitomycin C for 16 h Table 1 Relative¯uorescence intensity for p53 Treatment PAb122 PAb421 PAb240 PAb1620 PAb1605 Inhibition of p53 accumulation by butyrate. C3H10T1/2 cells pretreated for 18 h with 10 mM butyrate or mock-treated were incubated with 10 mg/ml mitomycin C for 16 h or left untreated. Cells were ®xed and immunstained with dierent p53-speci®c antibodies. PAb1605, a SV40-TAg-speci®c antibody, was used as negative control. The classi®cation of p53¯uorescence intensities on a scale from 0 to 4 was performed as described in Materials and methods investigated whether inhibition of DNA-damagedinduced p53 accumulation by butyrate was associated with an inhibition of mitomycin-C-induced cell cycle arrest. Mitomycin C alone induced a cell cycle arrest in early S phase 16 h after application ( Figure 4A , 0 mM butyrate). Pretreatment with butyrate for 18 h and subsequent mitomycin C application for another 16 h resulted in dose-dependent arrest of cells in G1 and G2/ M phase ( Figure 4B ). Thus, dose-dependent inhibition of p53 accumulation by butyrate in C3H10T1/2 cells is associated with a dose-dependent decrease of cells in the S phase of the cell cycle. The latter was con®rmed by the investigation of murine NIH3T3 cells (data not shown).
Additional cell cycle analysis of p53-negative ®broblasts treated for 34 h with 5 mM butyrate revealed that butyrate-induced G1 arrest occurred p53-independently ( Figure 5 ). We further examined p21
as a possible mediator of butyrate-induced G1 arrest by immunouorescence analysis, since this cyclin kinase inhibitor has also been reported to be involved in dierentiation (Steinman et al., 1994; Jiang et al., 1994) . Following treatment with butyrate the p21 waf1/cip1 content increased in C3H10T1/2 cells ( Figure 6a ) as well as in p53-de®cient cells (Figure 6b ). Thus, dierentiationassociated G1 arrest following butyrate treatment may be mediated through a p53-indpendent induction of p21 waf1/cip1 . The increase in p21 waf1/cip1 level by butyrate was already observed 3 h after addition to C3H10T1/2 cells and was a long lasting eect (56 h at least). In C3H10T1/2 cells, but not in p53-de®cient cells, p21 waf1/cip1 expression was also enhanced in response to mitomycin C (Figure 6a and b) . This con®rms that DNA-damage-induced p21 expression is mediated by p53. The p21 waf1/cip1 level in C3H10T1/2 cells reached a maximum after 7 h mitomycin C, then decreased, but was still elevated after 16 h mitomycin C. The cytoplasmic¯uorescence represents mostly unspeci®c staining by endogenous peroxidases since it was also observed in controls without antibody. Immunofluorescence data were veri®ed by¯ow cytometry (data not shown) and by Western blot analysis of p21 waf1/cip1 (Figure 6c ).
In¯uence of butyrate on p53-dependent apoptosis
To investigate whether butyrate inhibits p53-dependent apoptosis, C3H10T1/2 cells were pretreated with butyrate for 18 h. Then 10 mg/ml mitomycin C were added for 40 h and in parallel cells were treated with Figure 3 p53-independent induction of dierentiation by butyrate in C3H10T1/2 and p53-de®cient cells. In parallel to untreated cells (left), cells were incubated for 2 days with 10 mM butyrate (middle). Butyrate was removed from the cells after 2 days and cells were cultivated and passaged further for 5 days in normal medium (right). The arrows indicate binucleated cells butyrate only. To detect apoptotic DNA fragmentation, we used DNA end labelling with biotin-dUTP by terminal deoxynucleotidyl transferase (TUNEL assay) and FACS analysis. Percentages of apoptotic cells were determined by the relative cell number showing speci®c biotin-dUTP-incorporation in relation to control samples without terminal deoxynucleotidyl transferase. As a result, pretreatment with butyrate inhibited mitomycin-C-induced apoptosis partially (Figure 7 , lower row). However, lower doses of butyrate were more eective in inhibition of p53-dependent apoptosis than higher doses of butyrate. Equivalent results were obtained by DNA staining with propidium iodide and cytometric analysis of the apoptotic fraction (data not shown). Thus, in contrast to inhibition of p53 accumulation, the inhibition of p53-dependent apoptosis by butyrate did not correlate with the concentration of butyrate. Therefore, p53 cannot be the only regulator of p53-dependent apoptosis after pretreatment with butyrate.
Moreover, in C3H10T1/2 cells which were treated with butyrate only, induction of dierentiation was associated with onset of apoptosis in a small subset of cells (Figure 7, upper row) . Butyrate induced apoptosis p53-independently since it was also observed in p53-negative ®broblasts as shown by TUNEL assay on cover slides (Figure 8 , upper row). These p53-negative cells showed no induction of apoptosis 40 h after treatment with mitomycin C alone for the concentration used (Figure 8 , down on the left). Mitomycin C treatment had no in¯uence on butyrate-induced apoptosis (Figure 8 , lower row).
Interacting molecular mechanism of induced dierentiation and apoptosis
Though butyrate inhibited p53-dependent apoptosis in our experiments, inhibition of p53 accumulation did not correlate with inhibition of apoptosis. This discrepancy prompted us to further investigate the interference of butyrate-induced p53-independent differentiation and apoptosis with mitomycin-C-induced apoptosis. To better understand the interacting molecular mechanisms, we investigated dierentiationassociated and apoptosis-modulating proteins. Usinḡ ow cytometry analysis, we evaluated modulation of p53, c-Myc, and Bax content in response to butyrate . C3H10T1/2 and p53-de®cient ®broblasts were left untreated (1) or treated with 10 mM butyrate for 34 h (2). In parallel, C3H10T1/2 (positive control) and p53-de®cient ®broblasts (negative control) were treated with 10 mg/ml mitomycin C for 16 h (3) Figure 7 Mitomycin-C-and butyrate-induced apoptosis in C3H10T1/2 cells detected by¯uorimetric TUNEL assay. Cells were treated with butyrate as indicated and 18 h later either treated with 10 mg/ml mitomycin C for 40 h (lower row) or mock-treated (upper row). DNA fragmentation is shown in 3D-plots by incorporation of biotin-dUTP versus DNA content. The vertical axis represents the relative cell number. Percentages of apoptotic cells are given by the relative cell number showing speci®c biotin-dUTP-incorporation determined by control samples lacking terminal deoxynucleotidyl transferase. Data are representative of three experiments and mitomycin C. We chose and established¯ow cytometry analysis for these proteins because of its high sensitivity and the advantage to analyse on a single cell level. To avoid disturbing in¯uences of serum stimulation on the proteins analysed, cells were cultured for 36 h before they were treated in subcon¯uent condition with butyrate. Protein levels were evaluated at two time points: The ®rst time point 16 h after mitomycin C application was identical with the point of cell cycle investigation, 40 h after mitomycin application we examined apoptosis.
In agreement with the results obtained by indirect immuno¯uorescence, butyrate repressed p53 accumulation in a dose-dependent manner (Figure 9 , 16 h). During apoptosis (Figure 9 , 40 h) C3H10T1/2 cells still showed a butyrate-dependent inhibition of p53 accumulation; but p53 accumulation was diminished compared to 16 h mitomycin C treatment. In immuno¯uorescence analysis done in parallel, remaining adherent cells showed a delayed p53 accumulation 40 h after mitomycin C treatment. This was not due to turn-over of butyrate as controlled by experiments with conditioned medium (data not shown). The delayed p53 accumulation observed in immuno¯uorescence analysis was not re¯ected in¯ow cytometry analysis of all cells, since only a small percentage of the cells pretreated with 10 mM butyrate showed a reduced p53 accumulation. The greater sensitivity of cytometry analysis further permitted the investigation of the p53 steady state level. Interestingly, as con®rmed by immunoprecipitation with PAb122, no drastic changes of p53 upon treatment with butyrate were detected, except for 2 mM butyrate. During butyrate-induced apoptosis, a reproducible slight increase in p53 protein correlating with the concentration of butyrate occurred.
Upon treatment of cells with butyrate alone, c-Myc level ®rst decreased with the concentration used ( Figure 9 , 16 h). However, later on in association with butyrate-induced apoptosis, c-Myc content slightly increased in comparison to untreated control and in dependency of dose ( Figure 9 , 40 h). Additionally, butyrate-induced apoptosis was associated with a dose-dependent increase in Bax protein level. Sixteen hours after application of mitomycin C a slight rise of Bax protein was ®rst observed. At this time point the inhibition of p53 accumulation by butyrate correlated with a dose-dependent decrease in Bax protein. During mitomycin-C-induced apoptosis cMyc and Bax protein levels were increased in analogy to butyrate-induced apoptosis (Figure 9 , 40 h, 0 mM Butyrate). By low doses of butyrate, correlating with maximal inhibition of mitomycin-C-induced apoptosis, c-Myc and Bax protein content was drastically reduced, while with higher concentration of butyrate (10 mM) again an increase in c-Myc and Bax protein level was observd. However, c-Myc and Bax protein levels were still reduced compared to cells treated with mitomycin C only. Figure 9A and B demonstrate the speci®ty of the antibody reactions.
Discussion
It was of particular interest to study butyrate as an inhibitor of DNA-damage-induced p53 accumulation, since butyrate occurs naturally in millimolar concentrations in the human colon. In contrast to most earlier 0 mM 2 mM 5 mM 10 mM Mitomycin mock-treated
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Figure 8 p53-independent apoptosis induced by butyrate in p53-de®cient ®broblasts. For detection of apoptosis by TUNEL assay, cells were seeded on cover slides and treated with various concentrations of butyrate for 18 h. Then 10 mg/ml mitomycin C were applicated for 40 h (lower row) or cells were mock-treated (upper row). Biotin-dUTP-incorporation in cells with DNA fragmentation was visualized by¯uorescein-streptavidin using a Zeiss Axiophot microscope. The arrows indicate binucleated cells. Bar, 100 mm studies on butyrate, we chose a non-tumor cell line, C3H10T1/2, expressing wild-type p53 for our studies. In comparison with low passage ®broblasts from p53 knockout mice we investigated the interference of butyrate with the p53-dependent DNA damage response for the ®rst time systematically. Pretreatment of C3H10T1/2 cells with physiologically occurring concentrations of butyrate speci®cally inhibited p53 accumulation in response to mitomycin C, as demonstrated by a correlation between the inhibition and the concentration of butyrate used. Our data further indicate that the inhibition of mitomycin-Cinduced p53 accumulation by butyrate is a timedependent eect. The longer the incubation period with butyrate the stronger the inhibition. Inhibition of p53 accumulation by butyrate was con®rmed using additional cell lines and various antibodies. As reported by Gannon et al. (1990) and others (Graeber et al., 1994; Coleman et al., 1994; Siegel et al., 1995) PAb240 detects wild-type p53 in immuno¯uorescence analysis. Thus, PAb240 is not speci®c for mutated p53 in immuno¯uorescence analysis. Rather the cryptic epitope of PAb240 is exposed in conformational subsets of wild-type p53 or it is exposed after denaturation of the protein (Milner, 1995) .
A microscopically observable eect of butyrate was the promotion of cell dierentiation in C3H10T1/2 cells as well as in p53-de®cient ®broblasts. Simultaneously with cell dierentiation in response to butyrate, bi-and multinucleated cells arose. Others observed not only multinucleated cells, but also abnormal sets of chromosomes during exposure to butyrate (Utesch et al., 1993) . Both, multinucleated cells and chromosomal abnormalities, also occur in vivo in p53 knockout mice (Cross et al., 1995; Bouer et al., 1995) . Therefore, we ®rst presumed that butyrate-treated cells correspond to a p53-de®cient status. However, subsequent¯ow cytometric analysis as well as Western blot revealed no drastic changes of the p53 steady state level in normal C3H10T1/2 cells treated with butyrate. Only after treatment with 2 mM butyrate a signi®cant and reproducible decrease in p53 protein level was observed. Nevertheless, this observation does not exclude that transactivating functions, localization of p53 or DNA repair may be in¯uenced by butyrate. Figure 9 Fluorimetric analysis of p53, c-Myc, and Bax protein levels in C3H10T1/2 cells. Cells were pretreated with 2, 5, 10 mM butyrate for 18 h or left untreated and subsequently incubated with 10 mg/ml mitomycin C except for control cells. Sixteen hours and 40 h after mitomycin C application cells were ®xed and stained in parallel for cytometric analysis as described in Materials and methods. Relative¯uorescence intensities (DFL-1 and DFL-2) were evaluated by subtraction of unspeci®c¯uorescence intensity from total sample intensity. Speci®city of¯uorescence is shown in A for FL-1 (1: PAb1605; 2: PAb421; 3: c-Myc-speci®c antibody) and in B for FL-2 (4: rabbit normal serum; 5: Bax-speci®c antibody)
Treatment of C3H10T1/2 as well as of p53-de®cient cells with 2 or 5 mM butyrate induced cell cycle arrest in the G1 phase. In C3H10T1/2 cells, this differentiation-associated G1 arrest overlayed mitomycin-Cinduced early S phase arrest with increasing amounts of butyrate. In parallel, cells accumulated also in the G2/M phase of the cell cycle. Thus, dose-dependent inhibition of p53 accumulation by butyrate in C3H10T1/2 cells correlated with a dose-dependent decline of cells in S phase in response to mitomycin C. Our subsequent investigations of these cell cycle arrests revealed an induction of the cyclin-dependent kinase inhibitor p21 waf1/cip1 by butyrate in C3H10T1/2 as well as in p53-negative ®broblasts. Recently, this association of dierentiation commitment and p53-independent up-regulation of p21 waf1/cip1 has been reported for various agents (Steinman et al., 1994; Jiang et al., 1994) . Besides this, G1 arrest in response to diverse dierentiation stimuli, including butyrate, has been correlated with Rb hypophosphorylation in many cells (Chen et al., 1995; Gope and Gope, 1993) . Mitomycin C treatment also led to an increase in p21 waf1/cip1 in our experiments, but not in p53-de®cient cells. This con®rms the model that p21
, as a downstream eector of p53, mediates cell cycle arrest in response to genotoxic agents (Harper et al., 1993; Xiong et al., 1993; El-Deiry et al., 1994) . Both proteins, p53 (Sturzbecher et al., 1988) and p21 waf1/cip1 (Waga et al., 1994) , the latter in complex with the proliferating cell nuclear antigen (PCNA), have been demonstrated to inhibit directly DNA replication and may be critical regulators of DNA repair.
Apart from cell cycle arrest and dierentiation, we observed induction of apoptosis after exposure of C3H10T1/2 cells to butyrate. As we showed by experiments with p53-de®cient ®broblasts, butyrate induced apoptosis by a p53-independent mechanism. In conformity with our ®ndings in normal cells, butyrate-induced apoptosis has been shown to occur in colorectal carcinoma cells (Hague et al., 1993) and in the p53-de®cient leukemic HL60 line (Calabresse et al., 1993) through a p53-independent pathway. Using¯ow cytometry for C3H10T1/2 cells, we demonstrated that p53-independent apoptosis in response to butyrate was associated with an increase in Bax and c-Myc protein.
We yet cannot rule out by further investigation of p53-negative cells that this induction of Bax in C3H10T1/2 cells was due to simultaneous slight p53 induction during butyrate-induced apoptosis. In MCF-7 cells harbouring wild type p53 induction of dierentiation and apoptosis by a novel retinoid was also accompanied by p53-independent increase in p21 waf1/cip1 and bax expression, while bcl-2 mRNA level was decreased (Shao et al., 1995) . Besides, in p53-de®cient leukemic M1 cells expression of bcl-2 and bax was rapidly suppressed upon induction of dierentiation by interleukin-6 and dexamethasone (Lotem and Sachs, 1995) . However, parallels should be drawn with caution, because cells may respond dierentially and cell-type-speci®cally to various dierentiation stimuli.
Despite intense investigations on p53, the mechanism by which cells sense DNA repair capacity and drive to DNA repair or apoptosis remains unclear. In analogy to other studies on p53-de®cient cells (Lowe et al., 1993 (Lowe et al., , 1994 Lotem and Sachs, 1993) , our data indicate that missing p53 accumulation impairs apoptosis in response to mitomycin C. Moreover, attenuated p53 accumulation by butyrate in C3H10T1/2 cells was followed by an inhibition of mitomycin-C-induced apoptosis. However, despite dose-dependent inhibition of p53 accumulation, inhibition of p53-dependent apoptosis did not correlate with concentration of butyrate used; low doses were more eective in inhibition of DNA-damage-induced apoptosis than higher ones. Apparently, in addition to p53 protein, other apoptosis-promoting modulators seem to be repressed by butyrate; while with higher concentrations of butyrate apoptosis-stimulating eects seem to predominate. We con®rmed this assumption by further investigation of dierentiation and apoptosis modulators. Mitomycin-C-induced apoptosis correlated with induction of p53, c-Myc, and Bax protein. Butyrate repressed the induction of these positive apoptosis modulators in response to mitomycin C. Upon low doses of butyrate and in association with maximal inhibition of mitomycin-C-induced apoptosis, a maximal decline of c-Myc and Bax protein was observed. Suppression of apoptosis was also observed by others, when cells were initially exposed to stimuli of dierentiation and subsequently to cytotoxic agents (Forbes et al., 1992; Solary et al., 1993) . In analogy, p53-induced apoptosis in M1 cells by activation of a transfected temperature-sensitive p53 mutant was repressed by interleukin-6-induced dierentiation (Levy et al., 1993) .
In response to butyrate, a rapid decrease in c-myc mRNA as well as in c-Myc protein has been reported for several cell lines (Dony et al., 1985; Heruth et al., 1993; Steinman et al., 1994) . In our experiments this decrease in c-myc expression was ®rst re¯ected in a diminished synthesis of c-Myc protein correlating with the butyrate concentration used. However, with longer incubation period and in association with apoptosis, except for low doses of butyrate, we observed a dosedependent increase in c-Myc level. Since decline of cmyc mRNA has been shown to be a lasting eect of butyrate, other regulation mechanisms of c-Myc, perhaps apoptosis-speci®c mechanisms, must be aected by butryate. Therefore, dierentiation stimulus may predominate with low concentrations of butyrate since c-Myc is down-regulated, whereas with higher concentrations such as 10 mM butyrate increased c-Myc levels may override p21 waf1/cip1 -mediated cell cycle arrest (Steinman et al., 1994) and promote butyrate induced apoptosis. Our results con®rm data that p53 can act either as growth-inhibitor or apoptosis-inducer in the same cell depending on the c-myc expression (Saito and Ogawa, 1995) .
In transformed and normal ®broblast butyrate induces a long-lasting decline of p53 mRNA level (Dony et al., 1985; Toscani et al., 1988) . In transformed cells constitutively expressing high amounts of p53 protein this decrease in p53 mRNA has been reported to be followed by a decline of p53 protein level (Wintersberger and Mudrak, 1984; Goldberg et al., 1992) . We could con®rm this observation in transformed 3T6 cells by¯ow cytometry (data not shown). However, we found no marked reduction of p53 protein level by butyrate in normal C3H10T1/2 cells except for 2 mM butyrate, although preliminary results for C3H10T1/2 cells also showed a downregulation of p53 mRNA in response to butyrate. In addition to the mutually antagonistic transcriptional regulation of c-myc and p53 (Ragimov et al., 1993; Levy et al., 1993; Roy et al., 1994) , post-transcriptional regulation of p53 biosynthesis must be involved in normal cells and may be deregulated in transformed cells with high p53 expression. The mechanism through which butyrate inhibits p53 accumulation is not yet known, but preliminary experiments indicate a transcriptional mechanism (Janson, 1996) .
We assume from our data that the p53-independent induction of p21 waf1/cip1 in association with differentiation may account for anti-neoplastic in vitro eects of butyrate. This is supported by the observation that p21 waf1/cip1 suppresses tumorigenicity in vitro and in vivo (Chen et al., 1995; Yang et al., 1995) . Nevertheless, butyrate may also act as co-mutagen, since we present evidence that the induction of cell dierentiation by butyrate attenuates p53-dependent DNA damage response. Co-mutagenic features (Sankaranarayanan et al., 1984; Hojo et al., 1994) , even a direct mutagenic eect of butyrate (Utesch et al., 1993) , are reported by others. Both, anti-neoplastic and co-carcinogenic in vitro eects of butyrate may be correlated to in vivo observations, as epidemiological studies suggest an important role of butyrate in the prevention of colorectal cancer (Stemmermann and Yatani, 1972; Howe et al., 1992) . On the other hand, it has been observed that colon cancer shows a predilection for the left colon, which is the colonic region most dependent upon butyrate as an energy source (Roediger, 1980) . We assume this may be due to inhibition of p53-dependent apoptosis in the presence of butyrate. As shown by whole-body irradiation of normal mice, p53-dependent apoptosis was observed in the small intestine, but to a lower extent in the colon (Merritt et al., 1994) . Long-term incubation with butyrate may select cells with reduced susceptibility to terminal dierentiation and apoptosis (Berry and Paraskeva, 1988) .
In summary, our data indicate that induction of dierentiation by butyrate antagonizes p53-dependent DNA damage response, comprising p53 accumulation, cell cycle arrest, and apoptosis. Dierentiated cells may exhibit a lower susceptibility to DNA-damage-induced apoptosis in association with delayed and reduced p53 accumulation. Further investigation will elucidate whether reduced p53 accumulation in dierentiated cells is a common feature and whether dierentiated cells exhibit greater DNA damage repair capacity or posses lower sensitivity to DNA damage detection. Regarding tumor therapy, less dierentiated and rapidly proliferating tumors are generally concerned to be more susceptible to apoptosis triggered by anticancer drugs.
Materials and methods
Cell lines, cell culture and cell treatment
All cell lines were grown at 378C in a 5% carbon dioxide atmosphere in Dulbecco's modi®ed Eagle minimal essential medium (DMEM), supplemented with 5% fetal calf serum (FCS), 50 mg/ml gentamicin and 0.3 mg/ml glutamine. The cell lines were regularly checked for mycoplasma contamination with Hoechst 33258 dye staining (Chen, 1977) . C3H10T1/2 cells are immortalized, non-oncogenic mouse ®broblasts (Mondale and Heidelberger, 1976) containing wild-type p53 (Coleman et al., 1994) . p53-negative mouse ®broblasts were established from newborn p53-de®cient mice (TSG-p53 TM , from GenPharm International, purchased by Bomholdgard Breeding and Research Centre, Ry, licence no. 133) and were used until passage number seven. NIH3T3 cells are contact-inhibited NIH Swiss mouse embryo ®broblasts (ATCC CRL 1658). TC7 cells are spontaneously immortalized African green monkey kidney cells (Robb and Huebner, 1973) . For all experiments, cells were treated in the same way: in a subcon¯uent condition, ®rst incubated with butyrate (Sigma, Deisenhofen) for 18 h and then treated with 10 mg/ml mitomycin C (Medac, Hamburg) for another 16 h or 40 h.
Indirect immuno¯uorescence staining and p53 evaluation
Cells were grown on coverslips and ®xed as described previously (Fritsche et al., 1993) . For indirect immunouorescence, the p53-speci®c monoclonal antibodies PAb122 (Gurney et al., 1980) . PAb421 (Harlow et al., 1981) , PAb1620 (Ball et al., 1984) , PAb240 (Gannon et al., 1990) as well as a p53 non-reactive control antibody, PAb1605 (Ball et al., 1984) , were used. Biotinylated secondary antibodies and conjugates such as streptavidine-¯uorescein were obtained from Dianova, Hamburg. p21 waf-1/cip1 was detected by a rabbit polyclonal antibody from Oncogene Science (Hamburg) using the biotin/ streptavidin system and the TSA TM -Direct (Red) immunouorescence enhancing kit from NEN (Homburg).
For estimating the p53 content of cells, a classi®cation on a scale (0 to 4), combining the percentage of positive nuclei with their brilliance, was used as described previously (Fritsche et al., 1993) : (0) no speci®c¯uorescence or 55% of the nuclei positive; (1) either faint¯uorescence in 90% of the nuclei or about 20% of the nuclei positive; (2) at least 50% positive or bright, (3) at least 70% bright or brilliant or 90% positive; (4) more than 90% bright or brilliant nuclear uorescence. The results of quanti®cation by immunofluorescence correlate well with quanti®cation by Western blotting (Fritsche, 1991) .
Cell cycle analysis
Cells were trypsinized, washed in phosphate-buered saline (PBS) and ®xed in methanol/acetone (1 : 1) at 7208C for 10 min. After washing with PBS at 48C, cells were again pelleted at 400 g and 48C and then 1610 6 cells were resuspended in 400 ml RNase A (1 mg/ml; Sigma). After incubation on ice for 1 h, 20 ml propidium iodide (Sigma) dissolved in PBS (2 mg/ml) was added and incubated on ice for another 30 min. Cell cycle distribution was calculated with the CellFit software (Becton Dickinson, Heidelberg) using a FACSort (Becton Dickinson).
Detection of DNA fragmentation by TUNEL assay
In situ analysis of DNA fragmentation was performed using end-labelling of nicked DNA with biotin-conjugated dUTP by terminal deoxynucleotidyl transferase as described (Gorczyca et al., 1993) . Cells were trypsinized, washed in PBS and ®xed in 1% formaldehyde in PBS (pH 7.4) for 15 min on ice. After washing in PBS, cells were resuspended in 70% ethanol, stored for 1 h at 7208C and washed again. Then 5610 5 cells per sample were incubated at 378C for 30 min after resuspending in 50 ml of TUNEL buer (0.1 M sodium cacodylate (pH 7), 1 mM CoCl 2 , 0.1 mM dithiothreitol, 0.05 mg/ml bovine serum albumin, 10 units of terminal transferase, and 0.5 nM biotin-16-dUTP (all reagents from Boehringer Mannheim). In control samples terminal transferase was omitted. Subsequently, cells were rinsed with PBS, resuspended in 100 ml of a staining buer containing 2.5 g/ml streptavidin-¯uorescein (Dianova), 46 salinesodium citrate buer, 0.1% Triton X-100, and 5% (w/v) non-fat dry milk. Samples were incubated for another 30 min at room temperature, washed in PBS and resuspended 500 ml PBS, containing 5 mg/ml propidium iodide, 0.1% RNAse A and 0.1% Triton X-100. Following incubation for 10 min at room temperature in the dark, cells were washed in PBS and resuspended in 1% paraformaldehyde/0.9% NaCl. Flow cytometry was performed with a FACSort (Becton Dickinson) using Lysis II TM software (Becton Dickinson). The TUNEL assay was also performed with cells on coverslips and evaluated using a Axiophot microscope (Zeiss, Oberkochen).
Flow cytometric analysis
Fixation was carried out as described previously (Gazitt and Erdos, 1994) . Conditions for c-Myc immunofluorescence analysis as described (Alexandrova et al., 1995) were applied to¯ow cytometric analysis for the antigens investigated. Supernatant of murine monoclonal antibody PAb421 (Harlow et al., 1981) was used to stain p53. A rabbit polyclonal antibody was used to detect Bax (N-20, Santa Cruz). The murine anti-c-Myc clone 9E10 was obtained from PharMingen. This monoclonal antibody 9E10 is raised against a pre-C-terminal sequence of human c-Myc. The antibody reaction with murine and human cMyc is competeted by a peptide with the corresponding murine pre-C-terminal c-Myc sequence. An antibody reaction of a cross-reactive polyclonal antibody raised against the conserved N-terminus of c-Myc is not competible by the same peptide. Thus, 9E10 recognizes human and murine c-Myc (Siegel et al., manuscript submitted) .
Cells grown in Petri dishes were trypsinized and washed with PBS-4% FCS. Following ®xation in 1 ml of 1% paraformaldehyde in PBS for 20 min on ice, cells were washed with ice-cold PBS and then permeated with 1 ml of 0.1% Triton X-100 in PBS for 10 min on ice. After washing as before, the ®xed cells were incubated with 3% bovine serum albumine-10% goat serum for 30 min, to block nonspeci®c antibody binding. Staining was performed on 0.5610 6 cells/tube with hybridoma supernatant (1 : 10) or with puri®ed antibody (5 mg/ml for Bax; 10 mg/ml for c-Myc) for 1 h in the same buer on ice. Simultaneously, control samples for Bax analysis were incubated with rabbit IgG at twofold excess to determine nonspeci®c binding. PAb1605 hybridoma supernatant (IgG1) was used as murine isotype control. Unbound primary antibody was removed by washing with PBS. Samples were incubated with¯uorescein-conjugated goat F(ab) 2 fragments anti mouse IgG or Texas redconjugated goat-anti-rabbit IgG (both from Dianova) as secondary antibodies (1 : 100 in PBS-0.05% Tween 20) for 1 h on ice. After removing the secondary antibody, in some cases samples were treated for simultaneous staining of DNA content as described for the TUNEL assay. Data were acquired using a FACSort (Becton Dickinson) and analysed with the Lysis II TM software (Becton Dickinson).
Cell extraction
Monolayers of cells grown in 15 cm petri dishes were washed twice with ice-cold PBS, scraped o and pelleted. The pellet was then lysed in 400 ml of freshly prepared extraction buer (100 mM Tris/HCl pH 9.0, 100 mM NaCl, 0.5% NP40, 1% PEFA bloc, 1% aprotinine) for 30 min on ice. Extracts were cleared by centrifugation for 60 min at 10 000 g and 48C. After estimation of the protein content by the BioRad protein assay, equal amounts of protein were resuspended in sample buer (Laemmli, 1970) before being loaded on an SDS-gel.
SDS-polyacrylamide gel electrophoresis (SDS ± PAGE) and immunoblotting
Proteins were separated by 12.5% SDS ± PAGE on 0.75 mm mini-gels (Midget System, Pharmacia, Freiburg) and then transferred to a PVDF membrane (Schleicher and Schuell, Dassel) by semidry electroblotting (TE70, Hoefer, San Francisco). p21 waf-1/cip1 was detected by a polyclonal rabbit antibody (Oncogene Science, Hamburg) using the biotin/streptavidin system and enhanced chemoluminescence according to manufacturer's instructions (Amersham).
